US2009196850A1PendingUtilityA1

Anti-Kir Combination Treatments and Methods

49
Assignee: NOVO NORDISK ASPriority: Jan 6, 2005Filed: Jan 6, 2006Published: Aug 6, 2009
Est. expiryJan 6, 2025(expired)· nominal 20-yr term from priority
Inventors:Francois RomagnePeter Andreas Nicolai Reumert WagtmannJoakim Glamann
A61P 31/18A61P 43/00A61P 31/12A61P 35/00A61P 31/14A61K 38/2013C07K 16/2803A61K 2039/505
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.

Claims

exact text as granted — not AI-modified
1 . A method of treating cancer in a subject comprising administering a therapeutically effective amount of an anti-KIR antibody and an interleukin-2, an interleukin-2 derivative, or an interleukin-2 analogue to the subject. 
     
     
         2 . The method of  claim 1 , wherein the cancer is lung cancer. 
     
     
         3 . The method of  claim 1 , wherein neither the anti-KIR antibody nor the interleukin-2, interleukin-2 derivative, or interleukin-2 analogue contains Rituxan and/or Campath. 
     
     
         4 . The method of  claim 1 , wherein anti-KIR antibody and interleukin-2, interleukin-2 derivative, or interleukin-2 analogue are the sole pharmaceutically active agents administered to the subject for the treatment. 
     
     
         5 . The method of  claim 1 , wherein the anti-KIR antibody competes with DF200. 
     
     
         6 . The method of  claim 1 , wherein the anti-KIR antibody competes with 1-7F9. 
     
     
         7 . The method of  claim 1 , wherein the method comprises administration of human interleukin-2 to the subject. 
     
     
         8 . (canceled) 
     
     
         9 . The method of  claim 1 , wherein the antibody is 1-7F9. 
     
     
         10 . The method of  claim 1 , wherein the antibody comprises the VL and VH domains of 1-7F9. 
     
     
         11 . The method of  claim 1 , wherein the antibody comprises the VL and VH CDRs of 1-7F9. 
     
     
         12 . A pharmaceutically acceptable composition comprising an effective amount of an anti-KIR antibody and an interleukin-2, an interleukin-2 derivative, or an interleukin-2 analogue. 
     
     
         13 . The composition of  claim 12 , wherein the composition is free of Rituxan and/or or Campath. 
     
     
         14 . The composition of  claim 12 , wherein the composition is free of any other pharmaceutically active agents. 
     
     
         15 . The composition of  claim 12 , wherein the anti-KIR antibody competes with DF200. 
     
     
         16 . The composition of  claim 12 , wherein the anti-KIR antibody competes with 1-7F9. 
     
     
         17 . The composition of  claim 12 , wherein the interleukin, interleukin analogue, or interleukin derivative is human interleukin-2. 
     
     
         18 . (canceled) 
     
     
         19 . The composition of  claim 12 , wherein the antibody is 1-7F9. 
     
     
         20 . The composition of  claim 12 , wherein the antibody comprises the VL and VH domain of 1-7F9. 
     
     
         21 . The composition of  claim 12 , wherein the antibody comprises the VL and VH CDRs of 1-7F9. 
     
     
         22 . A method of treating a viral infection in a subject comprising administering a therapeutically effective amount of an anti-KIR antibody and an interleukin-2 protein to the subject. 
     
     
         23 . (canceled) 
     
     
         24 . The method of  claim 22 , wherein the viral infection is a HCV infection. 
     
     
         25 . The method of  claim 22 , wherein the viral infection is a HIV infection. 
     
     
         26 . The method of  claim 2 , wherein the anti-KIR antibody competes with DF200. 
     
     
         27 . The method of  claim 4 , wherein the anti-KIR antibody competes with DF200. 
     
     
         28 . The method of  claim 2 , wherein the anti-KIR antibody competes with 1-7F9. 
     
     
         29 . The method of  claim 4 , wherein the anti-KIR antibody competes with 1-7F9. 
     
     
         30 . The method of  claim 2 , wherein the method comprises administration of human interleukin-2 to the subject. 
     
     
         31 . The method of  claim 4 , wherein the method comprises administration of human interleukin-2 to the subject. 
     
     
         32 . The method of  claim 5 , wherein the method comprises administration of human interleukin-2 to the subject. 
     
     
         33 . The method of  claim 6 , wherein the method comprises administration of human interleukin-2 to the subject. 
     
     
         34 . The method of  claim 2 , wherein the antibody is 1-7F9. 
     
     
         35 . The method of  claim 4 , wherein the antibody is 1-7F9. 
     
     
         36 . The method of  claim 7 , wherein the antibody is 1-7F9. 
     
     
         37 . The method of  claim 2 , wherein the antibody comprises the VL and VH CDRs of 1-7F9. 
     
     
         38 . The method of  claim 4 , wherein the antibody comprises the VL and VH CDRs of 1-7F9. 
     
     
         39 . The composition of  claim 14 , wherein the anti-KIR antibody competes with DF200. 
     
     
         40 . The composition of  claim 14 , wherein the anti-KIR antibody competes with 1-7F9. 
     
     
         41 . The composition of  claim 14 , wherein the interleukin, interleukin analogue, or interleukin derivative is human interleukin-2. 
     
     
         42 . The composition of  claim 14 , wherein the antibody is 1-7F9. 
     
     
         43 . The composition of  claim 14 , wherein the antibody comprises the VL and VH domain of 1-7F9. 
     
     
         44 . The method of  claim 22 , wherein the anti-KIR antibody competes with DF200. 
     
     
         45 . The method of  claim 22 , wherein the anti-KIR antibody competes with 1-7F9. 
     
     
         46 . The method of  claim 22 , wherein the interleukin, interleukin analogue, or interleukin derivative is human interleukin-2. 
     
     
         47 . The method of  claim 22 , wherein the antibody is 1-7F9. 
     
     
         48 . The method of  claim 22 , wherein the antibody comprises the VL and VH domain of 1-7F9.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.